The results from the TIMER database showed that SLC41A3 expression was significantly increased in some cancers, including Bladder Urothelial Carcinoma (BLCA), cholangiocarcinoma (CHOL), Colon adenocarcinoma (COAD), Esophageal carcinoma (ESCA), Head and Neck squamous cell carcinoma (HNSC), LIHC, Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Rectum adenocarcinoma (READ) and stomach adenocarcinoma (STAD), compared with the normal tissues. Here, SLC41A3 is linked to cholangiocarcinoma.